The company has informed NICE that it will not provide an evidence submission for this appraisal. Therefore, we are suspending the appraisal while we consider the next steps.
| Status | Suspended |
| Technology type | Medicine |
| Decision | Selected |
| Reason for decision | Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources |
| Further information | In appraisal. |
| Process | STA Standard |
| ID number | 6335 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
| External Assessment Group | Kleijnen Systematic Reviews Ltd |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 17 December 2024 | Suspended. The company has informed NICE that it will not provide an evidence submission for this appraisal. Therefore, we are suspending the appraisal while we consider the next steps. |
| 22 May 2024 | Please note that following on from a request received from the company, the timelines for this appraisal have been paused and the appraisal is now anticipated to continue in late October 2024 when an Invitation to Participate will be re-issued. These timings are to enable the NICE appraisal timelines to more closely align with those of the ongoing regulatory process. |
| 22 May 2024 | Awaiting development. Please note that following on from a request received from the company, the timelines for this appraisal have been paused and the appraisal is now anticipated to continue in late October 2024 when an Invitation to Participate will be re-issued. These timings are to enable the NICE appraisal timelines to more closely align with those of the ongoing regulatory process. |
| 08 March 2024 | Invitation to participate |
| 11 December 2023 | Please note that following on from a request received from the company, the timelines for this appraisal have been revised and it is now anticipated to begin in early March 2024. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission. |
| 27 October 2023 - 20 November 2023 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 20 October 2023 | Following a request received from the company, NICE will be undertaking an evaluation of Andexanet alfa for reversing anticoagulation in people with intracranial haemorrhage (part review of TA697) [ID6335]. The evaluation is expected to start during early-October 2023 with a consultation on the draft scope. It is then anticipated that the final scope will be released along with an invitation to participate in the evaluation during late-November 2023. |
| 20 October 2023 | In progress |
For further information on our processes and methods, please see our CHTE processes and methods manual